Murdo Ferguson, MD

Colchester Research Group, Truro, Canada, Canada

Disclosure(s): GSK: Study related payments for training and the conduct of the study as a study site

Poster(s):

• (P-711) Persistence of Immunogenicity and Safety of the Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVPreF3 OA) Administered to Adults 50–59 Years of Age (YOA)
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT